{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6"],"submitter":["Brussino L"],"pubmed_abstract":["<h4>Introduction</h4>Severe eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients present CRSwNP.<h4>Methods</h4>This <i>post hoc</i> analysis of the ANANKE study (NCT04272463) reports data on the long-term effectiveness of benralizumab between SEA patients with and without CRSwNP (<i>N</i> = 86 and <i>N</i> = 75, respectively) treated for up to 96 weeks.<h4>Results</h4>Before benralizumab initiation, CRSwNP patients displayed longer SEA duration, greater oral corticosteroid (OCS) use and blood eosinophil count. After 96 weeks of treatment, the annual exacerbation rate (AER) decreased in both groups, with CRSwNP patie"],"journal":["Frontiers in allergy"],"pagination":["1501196"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11965627"],"repository":["biostudies-literature"],"pubmed_title":["Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a &lt;i&gt;post hoc&lt;/i&gt; analysis from the ANANKE study."],"pmcid":["PMC11965627"],"pubmed_authors":["Di Marco F","Altieri E","Del Giacco S","Brussino L","Malerba L","Rogliani P","D'Amato M","De Michele F","Menzella F","Vultaggio A","Canonica GW","Cameli P","Aliani M","Pelaia G","Romagnoli M","Schroeder JW","Senna G","Centanni S","Caiaffa MF","Caruso C","Bracciale P","Schino P"],"additional_accession":[]},"is_claimable":false,"name":"Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a &lt;i&gt;post hoc&lt;/i&gt; analysis from the ANANKE study.","description":"<h4>Introduction</h4>Severe eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients present CRSwNP.<h4>Methods</h4>This <i>post hoc</i> analysis of the ANANKE study (NCT04272463) reports data on the long-term effectiveness of benralizumab between SEA patients with and without CRSwNP (<i>N</i> = 86 and <i>N</i> = 75, respectively) treated for up to 96 weeks.<h4>Results</h4>Before benralizumab initiation, CRSwNP patients displayed longer SEA duration, greater oral corticosteroid (OCS) use and blood eosinophil count. After 96 weeks of treatment, the annual exacerbation rate (AER) decreased in both groups, with CRSwNP patie","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-07-14T03:02:25.48Z","creation":"2025-07-14T03:02:25.48Z"},"accession":"S-EPMC11965627","cross_references":{"pubmed":["40181809"],"doi":["10.3389/falgy.2025.1501196"]}}